TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TEAR
Previous SymbolNASDAQ:TEAR
CUSIPN/A
Phone858-455-6006
Debt
Debt-to-Equity RatioN/A
Current Ratio0.81
Quick Ratio0.69
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$27.12 million
Price / Sales0.03
Cash FlowN/A
Price / Cash FlowN/A
Book Value($2.32) per share
Price / Book-0.03
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-16,100,000.00
Net Margins-22.03%
Return on EquityN/A
Return on Assets-38.48%
Miscellaneous
Employees42
Outstanding Shares11,300,000
Market Cap$990,000.00
OptionableNot Optionable
TearLab (OTCMKTS:TEAR) Frequently Asked Questions
What is TearLab's stock symbol?
TearLab trades on the OTCMKTS under the ticker symbol "TEAR."
When did TearLab's stock split? How did TearLab's stock split work?
TearLab's stock reverse split on the morning of Friday, February 24th 2017. The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 23rd 2017. An investor that had 100 shares of TearLab stock prior to the reverse split would have 10 shares after the split.
How were TearLab's earnings last quarter?
TearLab Corp (OTCMKTS:TEAR) issued its earnings results on Wednesday, November, 7th. The medical research company reported ($0.02) earnings per share for the quarter. The medical research company had revenue of $6.15 million for the quarter. View TearLab's Earnings History.
When is TearLab's next earnings date?
Has TearLab been receiving favorable news coverage?
News coverage about TEAR stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TearLab earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of TearLab's key competitors?
Some companies that are related to TearLab include Amedica (AMDA), Delcath Systems (DCTH), Encision (ECIA), Regenicin (RGIN), Calmare Therapeutics (CTTC), AdvanSource Biomaterials Corpration (ASNB), Quantrx Biomedical (QTXB), Scivanta Medical (SCVM), Lombard Medical (EVARF), Hypertension Diagnostics (HDII), Oncologix Tech (OCLG), Prourocare Medical (PUMD), Revolutions Medical (RMCP), Delcath Systems (DCTHD) and Invuity (IVTY).
Who are TearLab's key executives?
TearLab's management team includes the folowing people:
- Mr. Elias Vamvakas, Exec. Chairman & Sec. (Age 59)
- Mr. Joseph S. Jensen, CEO & Director (Age 46)
- Mr. Michael Marquez, Chief Financial Officer (Age 36)
- Dr. Benjamin Sullivan Ph.D., Chief Scientific Officer (Age 42)
- Mr. Sam Fakhoury, VP of Quality, Compliance & Supply Chain
How do I buy shares of TearLab?
Shares of TEAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TearLab's stock price today?
One share of TEAR stock can currently be purchased for approximately $0.0801.
How big of a company is TearLab?
TearLab has a market capitalization of $990,000.00 and generates $27.12 million in revenue each year. TearLab employs 42 workers across the globe.
What is TearLab's official website?
How can I contact TearLab?
TearLab's mailing address is 150 La Terraza Blvd. Suite 101, Escondido CA, 92025. The medical research company can be reached via phone at 858-455-6006 or via email at [email protected]
MarketBeat Community Rating for TearLab (OTCMKTS TEAR)
MarketBeat's community ratings are surveys of what our community members think about TearLab and other stocks. Vote "Outperform" if you believe TEAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
